Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Research

Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study

Abstract

Androgen deprivation therapy (ADT) for prostate cancer (PCa) causes bone loss. Although we reported previously that risedronate significantly recovers bone mineral density (BMD) for up to 12 months, there have been no reports with longer follow-up periods to date. This study extended our earlier series extending the follow-up period to 24 months. Eligible patients had histologically confirmed PCa without lumbar spine metastasis and underwent ADT. Lumbar spine BMD, urinary deoxypyridinoline (uDPD) and serum bone alkaline phosphatase were measured at 6, 12 and 24 months. Among the total of 96 patients, we analyzed 26 and 18 patients in risedronate administration and control groups, respectively. BMD relative to the young adult mean ratio, uDPD and serum bone alkaline phosphatase of the risedronate administration group recovered significantly after 24 months compared with the control group (P<0.0001, P=0.0001, and P<0.0001, respectively). Transient blurred vision, malaise and vertigo were observed in 1 patient each among the 46 patients treated with risedronate within 28 days after first administration. Oral administration of risedronate is safe and effective for the recovery of ADT-induced bone loss in PCa patients even at 24 months after commencement of treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Purchase on Springer Link

Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

Layal Chaker, Salman Razvi, … Robin P. Peeters

References

  1. Ferlay J, Parkin DM, Steliarova-Foucher E . Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765–781.

    Article  CAS  PubMed  Google Scholar 

  2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ . Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225–249.

    Article  PubMed  Google Scholar 

  3. Akaza H, Hinotsu S, Usami M, Ogawa O, Kagawa S, Kitamura T et al. The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. J Urol 2006; 176: S47–S49.

    Article  PubMed  Google Scholar 

  4. Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR . Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer 2006; 106: 1708–1714.

    Article  PubMed  Google Scholar 

  5. Smith MR . Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes 2007; 14: 247–254.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Holzbeierlein JM, Castle EP, Thrasher JB . Complications of androgen-deprivation therapy for prostate cancer. Clin Prostate Cancer 2003; 2: 147–152.

    Article  CAS  PubMed  Google Scholar 

  7. Izumi K, Mizokami A, Sugimoto K, Narimoto K, Miwa S, Maeda Y et al. Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy. Urology 2009; 73: 1342–1346.

    Article  Google Scholar 

  8. Labrie F, Cusan L, Gomez JL, Belanger A, Candas B . Long-term combined androgen blockade alone for localized prostate cancer. Mol Urol 1999; 3: 217–226.

    CAS  PubMed  Google Scholar 

  9. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujisawa S, Shiraki M et al. Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 2001; 19: 331–337.

    Article  CAS  PubMed  Google Scholar 

  10. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT . Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181–186.

    Article  CAS  PubMed  Google Scholar 

  11. Morote J, Martinez E, Trilla E, Esquena S, Abascal JM, Encabo G et al. Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. Eur Urol 2003; 44: 661–665.

    Article  CAS  PubMed  Google Scholar 

  12. Krupski TL, Smith MR, Lee WC, Pashos CL, Brandman J, Wang Q et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer 2004; 101: 541–549.

    Article  PubMed  Google Scholar 

  13. Lipton A . Toward new horizons: the future of bisphosphonate therapy. Oncologist 2004; 9 (Suppl 4): 38–47.

    Article  CAS  PubMed  Google Scholar 

  14. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948–955.

    Article  CAS  PubMed  Google Scholar 

  15. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N . Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008–2012.

    Article  CAS  PubMed  Google Scholar 

  16. Saad F, Abrahamsson PA, Miller K . Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates. BJU Int 2009; 104: 1573–1579.

    Article  CAS  PubMed  Google Scholar 

  17. Ishizaka K, Machida T, Kobayashi S, Kanbe N, Kitahara S, Yoshida K . Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer. Int J Urol 2007; 14: 1071–1075.

    Article  CAS  PubMed  Google Scholar 

  18. Taxel P, Dowsett R, Richter L, Fall P, Klepinger A, Albertsen P . Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. BJU Int 2010; 106: 1473–1476.

    Article  CAS  PubMed  Google Scholar 

  19. Greenspan SL, Nelson JB, Trump DL, Wagner JM, Miller ME, Perera S et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol 2008; 26: 4426–4434.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Michaud LB, Goodin S . Cancer-treatment-induced bone loss, part 2. Am J Health Syst Pharm 2006; 63: 534–546.

    Article  CAS  PubMed  Google Scholar 

  21. Greenspan SL, Nelson JB, Trump DL, Resnick NM . Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007; 146: 416–424.

    Article  PubMed  Google Scholar 

  22. Michaud LB, Goodin S . Cancer-treatment-induced bone loss, part 1. Am J Health Syst Pharm 2006; 63: 419–430.

    Article  PubMed  Google Scholar 

  23. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P . A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007; 29: 1548–1558.

    Article  CAS  PubMed  Google Scholar 

  24. Kaufman JM, Johnell O, Abadie E, Adami S, Audran M, Avouac B et al. Background for studies on the treatment of male osteoporosis: state of the art. Ann Rheum Dis 2000; 59: 765–772.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 2004; 34: 195–202.

    Article  CAS  PubMed  Google Scholar 

  26. Delmas PD, Benhamou CL, Man Z, Tlustochowicz W, Matzkin E, Eusebio R et al. Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int 2008; 19: 1039–1045.

    Article  CAS  PubMed  Google Scholar 

  27. Moro-Alvarez MJ, Díaz-Curiel M . Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis. Clin Interv Aging 2008; 3: 227–232.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank Maki Morita for data collection.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to K Izumi.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Izumi, K., Mizokami, A., Sugimoto, K. et al. Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study. Prostate Cancer Prostatic Dis 14, 238–242 (2011). https://doi.org/10.1038/pcan.2011.10

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2011.10

Keywords

This article is cited by

Search

Quick links